Follow-up interview with Dr. Tsuyoshi Hamaguchi from the Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Japan.

Congratulations to the winners of this year’s Investigator Award! Each winner receives free registration for the 8th EAN Congress in Vienna and an award certificate.

On 2 October, 2021, the Council of Delegates of the World Federation of Neurology elected Prof. Wolfgang Grisold to be their next president.

This study aimed to describe gross and microscopic CNS pathology findings from the autopsies and correlate them with the clinical and laboratory characteristics of 45 patients with COVID-19 from Manaus, Amazonas, Brazil.

This study quantifies changes in neuro-oncological care during the height of the pandemic and investigates patient outcomes in 2020 compared to a historical control.

In this article the authors aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache.

From a sample of 208 consecutive non-neurological patients hospitalised for COVID-19 disease, 165 survivors were re-assessed at 6 months according to a structured standardised clinical protocol.

The objective of this study was to estimate whether the risk of death from COVID-19 in patients with multiple sclerosis (MS) exceeds that of the general population.

In this article the authors reviewed all vaccine related CVT published cases by April 30, 2021.

This study aims to determine the profile and possible mechanisms behind CNS inflammatory diseases in the context of COVID-19.

This bi-center longitudinal study evaluated symptoms in consecutive COVID-19 patients in the participating practices.

In this article the authors provide an overview on BTKi mechanisms relevant to COVID-19 infection and vaccination and review preliminary data on BTKi use in patients with COVID-19.

This Self-controlled case series study using national data on COVID-19 vaccination and hospital admissions.

In this study the authors investigated the effect of vaccination of health care workers in Scotland on the risk of coronavirus disease 2019 (COVID-19) among members of their households.

In this ongoing trial, the authors randomly assigned 44,165 participants aged 16 or older and 2,264 participants aged 12-15 to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo.